Dosiseskaleringsundersøgelse af vinpocetin hos raske frivillige
Fase I, Open Label, dosis-eskaleringsundersøgelse for maksimal tolereret vinpocetindosis hos raske frivillige
The objective of this study is to determine whether vinpocetine is safe when taken at higher doses.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The planned study seeks to provide preliminary data to assess the benefits and safety for vinpocetine to address cognitive problems in two groups of patients. One group are patients with epilepsy in whom cognitive problems are common, but there is currently no specific treatment available. Vinpocetine has been shown to improve memory in animals and also has anticonvulsant activity. The other group are people who suffer cognitive/behavioral problems from fetal exposure to alcohol or anticonvulsant drugs. In animals, vinpocetine has been shown to mitigate these deficits. We propose to extend our prior preliminary studies by conducting a Phase I study in healthy volunteers, a Phase I study in adolescents with cognitive impairments from fetal alcohol exposure, then Phase II studies in patients with epilepsy and in adolescents/adults with cognitive impairments from fetal alcohol or antiseizure medication (e.g., valproate) exposure. The proposed investigations are guided by prior PK and PD studies in animals and humans. They are designed to provide data on the dosages needed to provide levels comparable to effective animal studies and provide data on the potential efficacy and safety of vinpocetine in improving cognition in order to direct more definitive randomized trials in the future.
Specific Aim: To determine the maximum tolerated oral dose of vinpocetine in healthy adult volunteers and develop data on pharmacokinetic response curve for vinpocetine effects.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Jordan Seliger
- Telefonnummer: 650-460-9260
- E-mail: jseliger@stanford.edu
Studiesteder
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Stanford University
-
Kontakt:
- Jordan Seliger
- Telefonnummer: 650-460-9260
- E-mail: jseliger@stanford.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy adults 18-40 years old.
- Proficient English.
- Use of appropriate contraception if woman of childbearing potential.
Exclusion Criteria:
- Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression).
- Those who score >18 overall on the BDI-II or >0 for item #9 (suicidal thoughts) at screening.
- Use of centrally active medications.
- History of allergy to vinpocetine.
- IQ<80.
- BMI≥30.
- Pregnancy or lactation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Vinpocetine
Participants will take increasing, single doses of vinpocetine to determine maximum tolerated dose (MTD) based on intolerable side effects. 10 healthy volunteers enrolled, consented and screened; 4 patients failed screening; 6 subjects have taken study drug as single ascending doses. At 350mg dose, 6 subjects tested - 1/6 with intolerable side effect (vomiting). At 400mg dose, 2 subjects had marked nausea. Maxium Tolerated Dose = 350mg single dose. Six subjects to be enrolled in the TID dosing study. |
Increasing doses of vinpocetine to assess tolerability. |
|
Eksperimentel: Pharmacokinetics for TID dosing.
After completion of single dose MTD study, 6 healthy volunteers will receive TID doses to determine PK of TID dosing using blood concentrations. |
Increasing doses of vinpocetine to assess tolerability. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment-Related Adverse Events to determine maximum tolerated single dose and associated concentrations of vinpocetine at different doses.
Tidsramme: Approximately weekly treatments across ~4-6 visits per participant from enrollment until 2 weeks post each treatment.
|
Safety Outcome: intolerable side effects |
Approximately weekly treatments across ~4-6 visits per participant from enrollment until 2 weeks post each treatment.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Vinpocentine Concentrations
Tidsramme: Blood concentrations of vinpocetine are collected 1-2hrs post dose.
|
Blood concentrations of vinpocetine at different ascending doses. |
Blood concentrations of vinpocetine are collected 1-2hrs post dose.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Graviditetskomplikationer
- Fostersygdomme
- Stof-relaterede lidelser
- Kemisk inducerede lidelser
- Alkohol-relaterede lidelser
- Alkohol-inducerede lidelser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Føtale alkoholspektrumforstyrrelser
- vinpocetin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Protocol: 77615
- R61AA031291 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pending information from funding agency.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .